Investigation Report on China Insulin Glargine Market, 2010-2019
|発行||China Research and Intelligence||商品コード||331521|
|出版日||ページ情報||英文 30 Pages
|中国のインスリングラルギン市場の分析：2010年〜2019年 Investigation Report on China Insulin Glargine Market, 2010-2019|
|出版日: 2015年05月28日||ページ情報: 英文 30 Pages||
According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development.
Insulin glargine is the first long-acting insulin produced by simulating recombinant DNA technology. It was approved to be put into use by FDA in Apr. 2000 and then by the European Agency for the Evaluation of Medicinal Products (EMEA) in Jun. 2000. Since insulin glargine reports no obvious peak after using it for a long time, it has become the most widely-used insulin in the USA.
In China, the third generation of insulin is still in promotion period. Since its price is relatively high, it is mainly used in big cities. The second generation and the third generation of insulin will take the shape of stagger competition.
According to CRI's survey on some sample hospitals in China, the CAGR of insulin glargine in sample hospitals in China has exceeded 60% during the period of 2014-2015. Currently, the Chinese market is dominated mainly by Aventis Behring Gmbh (the trade name of insulin glargine is Lantus and the sales in 2014 exceeded USD 7 billion) and the generic drugs (the trade name of insulin glargine is Basalin) made by Gan & Lee Pharmaceutical. As the patent of Lantus expired in Feb. 2015, the global market structure is estimated to change in the next few years. On Sep.9, 2014, Eli Lilly and Company and Boehringer-ingelheim issued a joint statement that the insulin biosimilar - insulin glargine owned by them has been approved to come into market by the EU. On the other hand, in Chinese market, some local enterprises are also hastening the development of Lantus's generic drug.
With the improvement of living standards and the change of life styles in China, the incidence of diabetes has kept growing and the market size of diabetes drugs has expanded each year, exceeding CNY 20 billion in 2014 according to CRI's research. Currently in China, the second generation of recombinant human insulin is the mainstream of market. Having reduced the defects of the second generation of insulin and effectively shortened the length of treatment, the third generation of insulin products is expected to substitute the second generation gradually. It is predicated that insulin glargine is a potential product of growth among all three generations of insulin products.
Readers can get at least the following information through this report:
The author suggests the following groups of people purchase this report: